Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Assets (2022 - 2025)

Historic Current Assets for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $18.4 million.

  • Atara Biotherapeutics' Current Assets fell 7993.36% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year decrease of 7993.36%. This contributed to the annual value of $64.9 million for FY2024, which is 3629.66% down from last year.
  • As of Q3 2025, Atara Biotherapeutics' Current Assets stood at $18.4 million, which was down 7993.36% from $24.8 million recorded in Q2 2025.
  • Atara Biotherapeutics' Current Assets' 5-year high stood at $347.0 million during Q2 2022, with a 5-year trough of $18.4 million in Q3 2025.
  • For the 4-year period, Atara Biotherapeutics' Current Assets averaged around $150.2 million, with its median value being $106.4 million (2024).
  • Its Current Assets has fluctuated over the past 5 years, first crashed by 2261.32% in 2024, then plummeted by 7993.36% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' Current Assets (Quarter) stood at $295.1 million in 2022, then crashed by 65.48% to $101.9 million in 2023, then tumbled by 36.3% to $64.9 million in 2024, then crashed by 71.6% to $18.4 million in 2025.
  • Its Current Assets stands at $18.4 million for Q3 2025, versus $24.8 million for Q2 2025 and $27.2 million for Q1 2025.